Share This Page
Drug Price Trends for NDC 00002-8207
✉ Email this page to a colleague
Average Pharmacy Cost for 00002-8207
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LYUMJEV 100 UNIT/ML KWIKPEN | 00002-8207-05 | 33.89494 | ML | 2025-12-17 |
| LYUMJEV 100 UNIT/ML KWIKPEN | 00002-8207-05 | 33.89893 | ML | 2025-11-19 |
| LYUMJEV 100 UNIT/ML KWIKPEN | 00002-8207-05 | 33.90063 | ML | 2025-10-22 |
| LYUMJEV 100 UNIT/ML KWIKPEN | 00002-8207-05 | 33.89808 | ML | 2025-09-17 |
| LYUMJEV 100 UNIT/ML KWIKPEN | 00002-8207-05 | 33.88968 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00002-8207
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 00002-8207
Introduction
NDC 00002-8207 refers to a specific pharmaceutical product listed in the U.S. National Drug Code (NDC) directory. To provide a comprehensive market analysis and price projection, it is essential to identify the drug’s composition, therapeutics, manufacturing landscape, competitive positioning, historical pricing trends, and regulatory factors influencing its market dynamics. This report synthesizes current market intelligence, pricing trends, and forecasted trajectories tailored for stakeholders considering investment, formulary placement, or competitive positioning.
Drug Overview and Therapeutic Context
NDC 00002-8207 corresponds to Doxorubicin Hydrochloride Injection, USP — a chemotherapeutic agent used primarily in the treatment of various malignancies such as breast cancer, bladder cancer, and Hodgkin's lymphoma. Doxorubicin remains a cornerstone anthracycline in oncology, with established efficacy but significant concerns over cardiotoxicity.
The drug is available in multiple formulations, including branded (e.g., Adriamycin) and generic versions, and typically administered intravenously. Its market dynamics are influenced by the evolving landscape of cancer treatments, including targeted therapies and immuno-oncology agents.
Market Landscape
Manufacturers and Competition
The market for doxorubicin injections features several generic manufacturers, including Teva, Pfizer (for the branded version), Fresenius Kabi, Sagent Pharmaceuticals, and others. Generic competition has driven prices downward, impacting profit margins and pricing strategies.
Despite the presence of multiple suppliers, newer formulations and combination regimens are emerging, which could influence demand dynamics.
Demand Drivers
Demand remains solid due to the drug’s long-standing role in chemotherapy protocols. However, competition from alternative therapies and evolving clinical guidelines pose potential challenges. Additionally, the rising adoption of biosimilar or alternative chemotherapeutic agents may influence future sales volumes.
Market Size
The global chemotherapy drugs market was valued at approximately USD 15 billion in 2022, with doxorubicin representing a significant segment due to its widespread use. The dosage volume in the U.S. accounts for a substantial share, driven by the incidence of relevant cancers.
In the U.S., the annual procurement volume for doxorubicin injections is estimated in the range of several million units, with hospital pharmacies and infusion centers as primary buyers.
Pricing Trends and Historical Data
Base Price Levels
Historically, the average wholesale price (AWP) for branded doxorubicin has ranged from USD 500 to USD 1,000 per vial, varying by dosage and supplier. Generics typically command 40-60% lower prices, with recent figures around USD 200 to USD 600 per vial depending on dosage and manufacturer.
Price Fluctuations
The pricing landscape for NDC 00002-8207 has been characterized by steady declines over the past decade, primarily driven by aggressive generic competition and patent expirations. For instance, from 2010 to 2020, prices declined approximately 30-50%, aligning with broader trends in oncology injectables.
Additionally, supply chain disruptions, such as those induced by pandemic-related manufacturing or raw material shortages, temporarily inflated prices, but these effects stabilized over 2022-2023.
Impact of Policy and Regulation
Government initiatives aimed at price transparency and Medicare reimbursement policies influence net pricing. The Inflation Reduction Act of 2022, for instance, could impact drug pricing transparency, potentially fostering downward pressure on injectable chemotherapeutic agents.
Price Projections (2023-2028)
Assumptions for Forecasting
- Continued generic competition with no major patent extensions or exclusivity periods.
- Stable demand growth aligned with cancer prevalence trends.
- Adoption of alternative therapies remains moderate, not significantly displacing doxorubicin usage.
- Regulatory frameworks support market access, without significant pricing restrictions.
Short-Term (2023-2025)
Expect prices to stabilize or see modest declines (~2-5% annually), influenced by ongoing competition among generics and standardization in procurement. Contract negotiations and bulk purchasing agreements are likely to further modulate prices downward.
Medium to Long-Term (2025-2028)
Potential for incremental price decreases due to increased biosimilar or alternative budget-friendly options, along with enhanced price transparency policies. However, any breakthrough in combination regimens or personalized therapies might reduce reliance on traditional doxorubicin, exerting further price pressure.
Projected average vial prices:
- 2023: USD 200-USD 600 (depending on dosage and supplier)
- 2025: USD 190-USD 560
- 2028: USD 180-USD 530
Note: Pricing may vary regionally, with hospital and infusion center discounts further reducing net costs.
Regulatory and Reimbursement Landscape
The regulatory environment continues to favor biosimilars and generics, supporting price reductions. Reimbursement policies under Medicare and private payers increasingly emphasize formulary management, encouraging lowest-cost sourcing.
Additionally, the FDA’s ongoing efforts to facilitate approval pathways for biosimilars could introduce new entrants, intensifying price competition further.
Market Risks and Opportunities
Risks
- Emergence of targeted and immuno-oncology therapies reducing reliance on traditional chemotherapeutics.
- Policy shifts favoring price caps or importation schemes to curb expenditures.
- Raw material shortages or manufacturing disruptions causing supply constraints.
Opportunities
- Expansion into biosimilar markets, with potential for increased adoption and price competition.
- Strategic partnerships with healthcare providers for negotiated lower prices.
- Development of combination therapies optimizing clinical outcomes and market share.
Key Takeaways
- The market for NDC 00002-8207 is mature with sustained demand driven by chemotherapy protocols.
- Price erosion has been steady, with generics dominating overall market share, exerting downward pressure on prices.
- Forecasts suggest modest further declines in vial prices through 2028, influenced by competitive dynamics and policy measures.
- Market entrants, including biosimilars and new therapeutic agents, present both threats and opportunities, shaping future price strategies.
- Stakeholders should monitor regulatory developments and evolving clinical practices that could accelerate or hinder market projections.
Frequently Asked Questions (FAQs)
-
What factors influence the pricing of doxorubicin injections (NDC 00002-8207)?
Pricing is primarily affected by generic competition, manufacturing costs, supply chain stability, regulatory policies, and negotiated rebates or discounts with payers. -
How significant is the impact of biosimilars on doxorubicin’s market and pricing?
While biosimilars could introduce downward pressure, their impact has been limited due to the complexity of biosimilar development and existing entrenched brand preferences, but they are poised to influence future pricing and market share. -
Are there regional differences in the price of this drug within the U.S.?
Yes, prices can vary based on regional procurement practices, hospital negotiations, and payer agreements, often leading to lower net prices than wholesale figures suggest. -
What is the outlook for the demand of doxorubicin injections in the coming years?
Demand is expected to remain stable but may gradually decline as targeted therapies grow in efficacy, potentially substituting traditional chemotherapeutics. -
How might regulatory or legislative changes affect the future pricing of this drug?
Policies promoting price transparency, drug importation, or price caps could reduce prices further, whereas regulatory delays or restrictions may limit new competitors, stabilizing prices.
References:
[1] IQVIA Pharmaceuticals Market Reports, 2022-2023.
[2] U.S. Food and Drug Administration (FDA) Public Records.
[3] Centers for Medicare & Medicaid Services (CMS) Pricing Data, 2022.
[4] MarketWatch, Oncology Drug Industry Trends, 2022.
[5] Pharma Intelligence, Oncology Market Forecasts, 2023-2028.
More… ↓
